Billion-dollar biosim maker mulls $500M Hong Kong IPO
A Chinese biosimilar maker valued at $1.5 billion might be the first to list its stock on Hong Kong’s exchange under new rules allowing startups …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
